BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9865707)

  • 1. Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer.
    Dieras V
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):18-22. PubMed ID: 9865707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
    Pagani O
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):23-6. PubMed ID: 9865708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
    Nabholtz JM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):7-13. PubMed ID: 10426453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
    Sparano JA
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I/II study of dose-intense doxorubicin/paclitaxel/cyclophosphamide with peripheral blood progenitor cells and cytokine support in patients with metastatic breast cancer.
    Rahman Z; Champlin R; Rondon G; Frye D; Valero V; Mehra R; Hortobagyi G
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-77-S17-80. PubMed ID: 9374100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin and paclitaxel, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Paaske T; Jensen BV
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):23-7. PubMed ID: 8893895
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Docetaxel in combination chemotherapy for metastatic breast cancer.
    Khayat D; Antoine E
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel (Taxotere) in combination: a step forward.
    Burris HA; Fields S; Peacock N
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BV
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):13-8. PubMed ID: 8629030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doxorubicin plus paclitaxel in advanced breast cancer.
    Dombernowsky P; Boesgaard M; Andersen E; Jensen BV
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-15-S17-8. PubMed ID: 9374086
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel plus doxorubicin in breast cancer: an Italian experience.
    Frassineti GL; Zoli W; Silvestro L; Serra P; Milandri C; Tienghi A; Gianni L; Gentile A; Salzano E; Amadori D
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-19-S17-25. PubMed ID: 9374087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I studies of combined paclitaxel/epirubicin and paclitaxel/epirubicin/cyclophosphamide in patients with metastatic offast cancer: the French experience.
    Catimel G; Spielmann M; Dieras V; Tubiana-Hulin M; Bonneterre J; Pouillart P; Kayitalire L; Guastalla JP; Graffand N; Garet F; Dumortier A; Pellae-Cosset B
    Semin Oncol; 1997 Feb; 24(1 Suppl 3):S8-12. PubMed ID: 9071333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience.
    Sledge GW; Robert N; Sparano JA; Cobeligh M; Goldstein LJ; Neuberg D; Rowinsky E; Baughman C; McCaskill-Stevens W
    Semin Oncol; 1994 Oct; 21(5 Suppl 8):15-8. PubMed ID: 7939756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
    Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BW; Ejlertsen B
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Doxorubicin/taxane combinations: cardiac toxicity and pharmacokinetics.
    Sparano JA
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):14-9. PubMed ID: 10426454
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evolution in the treatment of advanced breast cancer.
    Crown J
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
    Holmes FA
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.